sulfapyridine Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.   NCATS

Chemistry

  • SMILES: NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=N2
  • InChIKey: GECHUMIMRBOMGK-UHFFFAOYSA-N
  • Mol. Mass: 249.289
  • ALogP: 1.46
  • ChEMBL Molecule:
    sulfapyridine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

concord 693 | dagenan | eubasin | n(1)-2-pyridylsulfanilamide | n(1)-pyridylsulfanilamide | n-2-pyridylsulfanilamide | piridazol | pirodazole | plurazol | pyridazol | solfapiridina | streptosilpyridine | sulfanilamidopyridine | sulfapiridina | sulfapyridin | sulfapyridine | sulfapyridinum | sulfidin | sulfidine | sulphapyridine

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Dermatitis Herpetiformis (approved 1939)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue